Evidence map›Paper›PMID 26218271›Full record

ArticlePloS one2015

Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes.

Mark W Julian, Heather R Strange, Megan N Ballinger, Richard S Hotchkiss, Tracey L Papenfuss, Elliott D Crouser

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mark W JulianDorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America.
Heather R StrangeCollege of Veterinary Medicine, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America.
Megan N BallingerDorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America.
Richard S HotchkissDepartments of Anesthesiology, Medicine and Surgery, Washington University School of Medicine, St. Louis, MO, United States of America.
Tracey L PapenfussCollege of Veterinary Medicine, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America.
Elliott D CrouserDorothy M. Davis Heart and Lung Research Institute, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine, Wexner Medical Center, Columbus, OH, United States of America.
The Ohio State University Wexner Medical Center · USThe Ohio State University · USWashington University in St. Louis · US

Funding

Dendritic Cell Activation by Mitochondrial Transcription Factor AR21AI083912 · NIAID · OHIO STATE UNIVERSITY · PI CROUSER, ELLIOTT D · 2009 to 2010
$413k
Induction of Inflammation by Mitochondrial ProteinsR03AI062740 · NIAID · OHIO STATE UNIVERSITY · PI CROUSER, ELLIOTT D · 2005 to 2006
$148k
NIAID NIH HHS R03 AI062740NIAID NIH HHS R03-AI62740NIAID NIH HHS R21 AI083912NIAID NIH HHS R21-AI083912
6 · The paper itself

Abstract

objectiveImmune suppression during critical illness predisposes to serious infections. We sought to determine the mechanisms regulating tolerance and cross-tolerance to common pro-inflammatory danger signals in a model that recapitulates the intact in vivo immune response. MATERIALS AND

methodsFlt3-expanded splenocytes obtained from wild-type or matching IRAK-M knockout (IRAK-M-/-), C57BL/6, male mice (8-10 weeks old) were treated repeatedly or alternately with either LPS or CpGA DNA, agonists of Toll-like receptor (TLR)-4 and -9, respectively, over successive 24-hour periods. Supernatants were collected following each 24-hour period with cytokine release (ELISA) and splenocyte IRAK-M expression (Western blot) determined. Tolerance and cross-tolerance were assessed in the absence or presence of programmed death receptor (PD)-1 blocking antibody or IL-7 pre-treatment. MAIN

resultsSplenocytes notably exhibited both tolerance and cross-tolerance to subsequent treatments with either LPS or CpGA DNA. The character of tolerance and cross-tolerance in this model was distinct following initial LPS or CpGA treatment in that TNFα and IFNγ release (not IL-10) were suppressed following LPS; whereas, initial CpGA treatment suppressed TNFα, IFNγ and IL-10 release in response to subsequent stimulation (LPS or CpGA). Tolerance and cross-tolerance were unrelated to IL-10 release or PD-1 but were attenuated in IRAK-M-/- splenocytes. IL-7 significantly suppressed IRAK-M expression and restored TNFα and IFNγ production without influencing IL-10 release.

conclusionsIn summary, acute immune tolerance and cross-tolerance in response to LPS or CpGA were distinct in that LPS selectively suppressed pro-inflammatory cytokine responses; whereas, CpGA suppressed both pro- and anti-inflammatory responses. The induction of tolerance and cross-tolerance in response to common danger signals was mechanistically unrelated to IL-10 or PD-1 but was directly influenced by IRAK-M expression. IL-7 reduced IRAK-M expression and attenuated immune tolerance induced by either LPS or CpGA, and thus may be useful for reversal of immune tolerance in the setting of critical illness.

Indexed as

Immune ToleranceAnimalsInterferon-gammaInterleukin-10Interleukin-1 Receptor-Associated KinasesInterleukin-7LipopolysaccharidesMaleMiceMice, KnockoutOligodeoxyribonucleotidesSpleenToll-Like Receptor 4Toll-Like Receptor 9Tumor Necrosis Factor-alphaCPG-oligonucleotideIL10 protein, mouseInterferon-gammaInterleukin-10Interleukin-1 Receptor-Associated KinasesInterleukin-7interleukin-7, mouseIrak3 protein, mouseLipopolysaccharidesOligodeoxyribonucleotidesTlr4 protein, mouseTlr9 protein, mouseToll-Like Receptor 4Toll-Like Receptor 9Tumor Necrosis Factor-alpha

Identifiers

PMID26218271
PMCPMC4517781
OpenAlexW2138849457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.